Congenital diaphragmatic hernia (CDH) is often associated with severe pulmonary hypoplasia resulting in hypoxemic respiratory failure unresponsive to advanced medical management including the use of inhaled nitric oxide (iNO). For these patients, extracorporeal membrane oxygenation (ECMO) serves as the last potentially effective treatment choice. Since the efficacy of iNO in this patient population is not known and since most neonatal intensive care units using iNO for the treatment of these critically ill neonates do not provide ECMO, the ability to more accurately predict which patient is at risk for failing medical management with iNO and requires a timely transfer to an ECMO center can be life saving. Therefore, in this study, we sought to determine the risk factors for the need for ECMO in a cohort of 27 neonates with isolated left CDH and hypoxemic respiratory failure treated with iNO.
INTRODUCTION
Hypoxic respiratory failure is a frequent complication of congenital diaphragmatic hernia (CDH) carrying a mortality rate of 18 to 47%. [1] [2] [3] [4] [5] [6] [7] Approximately one-half of the critically ill neonates with CDH and hypoxic respiratory failure are supported with ECMO. 4, [8] [9] [10] The use of the selective pulmonary vasodilator, inhaled nitric oxide (iNO), has been beneficial in many neonatal disease processes presenting with pulmonary hypertension. [11] [12] [13] [14] [15] However, a randomized trial of early iNO treatment in infants with CDH did not show an improvement in survival or a decrease in ECMO utilization. 8 Despite these findings and the high treatment failure rate, iNO continues to be frequently used in the medical management of neonates with CDH and pulmonary hypertension in facilities without ECMO availability. However, due to the unavoidable delay associated with the process of transfer to an ECMO center, patients who do not respond to medical management with iNO in a facility without ECMO availability may be at risk for adverse short-and long-term outcomes. Thus, definition of factors predictive of the need of ECMO in this patient population would increase early identification of neonates at high risk for failing medical management with iNO and mitigate the delays in the initiation of the frequently life-saving bypass support.
Although previous studies have addressed outcomes that combine death and ECMO in neonates with CDH, 5, 8 predictors of failure of medical management with iNO and the need for ECMO support have not been successfully identified. Therefore, in the present study, we retrospectively examined the clinical data of all neonates with isolated left CDH and hypoxemic respiratory failure admitted to our center during a 2-year period that received iNO as part of the medical management after admission to our center. Using logistic regression analysis, we then assessed the risk factors predicting the need for ECMO support in this patient population.
METHODS
Neonates with isolated left-sided CDH and hypoxic respiratory failure admitted to our institution between January 1998 and December 31, 1999 were identified. None of these neonates had received iNO prior to transfer to our facility and iNO administration was initiated in an attempt to treat their hypoxic respiratory failure. After obtaining Institutional Review Board approval, the medical charts of these patients were reviewed retrospectively and demographics, ventilatory support, presence of airleak syndrome requiring chest tube placement, data of blood gas analysis after 6 hours of iNO administration and initiation of ECMO support were noted. The diagnosis of CDH was confirmed in all of the 27 patients at the time of surgery or postmortem.
During the study period, strict clinical guidelines were used in our center to standardize iNO therapy, to provide adequate lung inflation and cardiovascular support, and to recognize treatment failures and the need for ECMO. Indications for iNO therapy included the presence of clinical signs of PPHN, echocardiographic evidence of suprasystemic pulmonary pressures and a PaO 2 of <80 mmHg on 100% FiO 2 with optimal lung inflation. Inhaled nitric oxide was administered at 20 ppm in all patients during the first 6 hours of treatment.
The criteria for the initiation of ECMO support included an oxygenation index (OI) of >40 for 4 hours despite optimized medical management on iNO, a PaO 2 of <40 for 2 hours and/or the development of a cardiovascular failure refractory to aggressive use of volume and pressors/inotropes. The OI was calculated according to the conventional formula (OI ¼ mean airway pressure (MAP) Â FiO 2 /postductal PaO 2 ). Patients were not eligible for ECMO support if they were <34 weeks gestational age, had a birth weight of <2000 g, developed significant coagulopathy or uncontrolled bleeding (except for pulmonary hemorrhage) and/or presented with lethal congenital anomalies, evidence of severe irreversible brain injury or an intraventricular hemorrhage of >Grade I.
Statistical Analysis
Distributions of continuous variables were tested for normality. For normally distributed variables (birth weight and MAP), equality of the means was tested by the t-test. For all other continuous variables, equality of distribution was tested by the Mann-Whitney U test. For categorical and continuous variables recorded into ordinal measures, the distribution or proportions of patients between groups were compared by the Fisher's exact test. For categorical and continuous variables a p<0.05 was considered significant and data are given as mean±SD unless noted otherwise.
Logistic regression analysis was used to investigate the relationship between the need for ECMO and a set of risk factors. After univariate analysis, variables having a p-value of <0.2 were selected into the final logistic regression model. The only such variable in our final model was the presence of an airleak. The analyses were performed with the SAS System, release 8.0, SAS Institute Inc., Cary, NC.
RESULTS
A total of 27 infants with left CDH and hypoxic respiratory failure were transferred to our institution for ECMO evaluation. None of the patients had received iNO prior to their transfer to our center. In all, 15 neonates fulfilled the criteria for initiation of ECMO support (ECMO Group), while 12 patients could be managed medically (Non-ECMO Group). There were no significant statistical differences in birth weight, age at transfer or Apgar scores between the two groups ( Table 1) . Ventilator settings and the results of blood gas analysis after 6 hours of admission and iNO treatment are described in Table 2 . There were no statistically significant differences in MAP, FiO 2 , pH, postductal PaO 2 and PaCO 2 between The clinically relevant variables selected for the univariate logistic regression analysis are described in Figure 1 . We found that the presence of an airleak was the only variable statistically significantly associated with the need for ECMO. Indeed, neonates with isolated left-sided CDH treated with iNO for 6 hours that had developed airleaks before admission and the initiation of iNO treatment were 22 times more likely to require ECMO support (OR ¼ 22, 95% CI ¼ 2.18 to 222) than those that did not have airleaks. A marginal significant likelihood for ECMO support was also noted for patients with a postductal PaO 2 of <60 mmHg after 6 hours on iNO (p ¼ 0.057). The other variables in the model were not significant for prediction of ECMO support.
Survival to discharge or at the time of transfer back to the referring institution was 10 of the 12 in the non-ECMO Group versus eight out of the 15 in the ECMO Group (83.3% versus 53.3%, respectively; p<0.05).
DISCUSSION
According to our findings, neonates with left-sided CDH and hypoxic respiratory failure treated with iNO for 6 hours were 22 times more likely to require ECMO if they presented with an airleak requiring chest tube placement prior to iNO therapy. The other variables in our analysis assessed at 6 hours of iNO administration were not statistically significant predictors of ECMO support. In previous reviews of neonates with CDH, significant predictors of death or ECMO included prematurity, low Apgar scores, best postductal PaO 2 , OI, associated anomalies and prenatal diagnosis. 2, 3, 5, 7 Attempts to apply outcomes-based predictive models for ECMO prior to the era of iNO administration have been successful. 10 Based on these data, a recent review has recommended transfer of neonates with CDH and hypoxic respiratory failure to an ECMO center with an OI of >15 at 6 hours of life, a best postductal PaO 2 of <100 mmHg, or a prenatal diagnosis of CDH. 5 These authors found that only one patient that met these criteria and was not treated with ECMO survived and postulated that mortality may have been preventable in some neonates had they been transferred earlier. 5 In our logistical regression model, the only statistically significant predictor of the need for ECMO support in infants with left CDH and hypoxic respiratory failure after 6 hours of iNO was the presence of an airleak requiring chest tube placement. Our findings indicate a significant association with a 22-fold increase in the probability that neonates with CDH treated with iNO require ECMO support if they develop an airleak. It is important to note that the relatively small sample size of this study may have rendered the logistic regression model underpowered to detect additional factors other than airleak to predict the need for ECMO in this patient population.
The development of airleak and the subsequent requirement of the need for ECMO in our patients may be an indicator of significant pulmonary hypoplasia. Several lines of evidence support this notion. Neonates with CDH requiring emergent preoperative chest tube placement have been found to have a 71.4% mortality rate. 6 Furthermore, in a study performed in a non-ECMO center, pneumothorax occurred in 20% of neonates with CDH and was associated with increased mortality. 1 The association was highly significant, with a pneumothorax being present in 4% of survivors and 41% of neonates who died. 1 It is of note that a possible confounding variable in our study may have been the impact of the presence of an airleak on the decision to proceed with the initiation of ECMO support.
It is generally accepted that all neonates with CDH in hypoxic respiratory failure requiring iNO treatment represent a very highrisk population. A worrisome finding of our study is that variables including birth weight, age at transfer, blood gas values after 6 hours of treatment with iNO, Apgar scores and PaO 2 >100 mmHg did not predict a decreased need for ECMO. The lack of such statistical significance infers that a recommendation to initially attempt to treat these infants in non-ECMO centers cannot be made. The absence of clinical predictors for ECMO support in this high-risk population necessitates the use of judicious clinical insights and the careful consideration of all of the variables. The results of our study are the first to indicate that all infants with CDH and hypoxic respiratory failure treated with iNO that develop an airleak should be immediately referred to an ECMO center. In these cases, a close collaboration among perinatologists, neonatologists and pediatric surgeons and the availability of a well- established transport system and an experienced ECMO center may optimize outcomes.
